Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism

[1]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[2]  Kiyoshi Inoue,et al.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.

[3]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[4]  R. Tyndale,et al.  Nicotine metabolism defect reduces smoking , 1998, Nature.

[5]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[7]  J. Stengård,et al.  Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C‐oxidase , 1998, FEBS letters.

[8]  J. Yokota,et al.  CYP2A6 gene deletion reduces susceptibility to lung cancer. , 1999, Biochemical and biophysical research communications.

[9]  G. Coetzee,et al.  Genetic variation of CYP2A6, smoking, and risk of cancer , 1999, The Lancet.

[10]  T. Kamataki,et al.  A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  Y. Funae,et al.  Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[13]  K. Kitagawa,et al.  The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. , 1999, Biochemical and biophysical research communications.

[14]  O. Pelkonen,et al.  CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis. , 1997, Pharmacogenetics.

[15]  J. Idle,et al.  Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 , 1998, European Journal of Clinical Pharmacology.

[16]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[17]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[18]  J. Idle,et al.  A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[19]  A. Wedell.  Molecular genetics of congenital adrenal hyperplasia (21‐hydroxylase deficiency): implications for diagnosis, prognosis and treatment , 1998 .

[20]  A. Parkinson,et al.  Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. , 1992, Archives of biochemistry and biophysics.

[21]  D. Pompon,et al.  Chimeras of the human cytochrome P450 1A family produced in yeast. Accumulation in microsomal membranes, enzyme kinetics and stability. , 1994, European journal of biochemistry.

[22]  D. Pompon,et al.  Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. , 1990, Biochimie.

[23]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[24]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[25]  B. Green,et al.  Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. , 1999, Pharmacogenetics.

[26]  P. Reisdorf,et al.  Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. , 1993, Gene.

[27]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[28]  M Ingelman-Sundberg,et al.  A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. , 1997, Molecular pharmacology.

[29]  T. Shimada,et al.  Purification and characterization of human liver microsomal cytochrome P-450 2A6. , 1991, Molecular pharmacology.

[30]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[31]  A. Aitio.  A simple and sensitive assay of 7-ethoxycoumarin deethylation. , 1978, Analytical biochemistry.

[32]  E. Krynetski,et al.  High yield expression of functionally active human liver CYP2D6 in yeast cells. , 1995, Pharmacogenetics.

[33]  J. Idle,et al.  Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. , 1992, Journal of chromatography.

[34]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.